MRM (MEDIROM Healthcare Technologies) 1-Year Sharpe Ratio: -0.25 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MRM MEDIROM Healthcare Technologies Inc MRM
53 GF Score
Price $0.93
GF Value $4.07
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is MEDIROM Healthcare Technologies 1-Year Sharpe Ratio?

MEDIROM Healthcare Technologies MRM +2.25% 53 1-Year Sharpe Ratio is -0.25 as of Aug. 04, 2026. GuruFocus rates MRM with a GF Score™ of 53/100 and a GF Value™ of $4.07 (Possible Value Trap). The stock has 8 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-04), MEDIROM Healthcare Technologies's 1-Year Sharpe Ratio is -0.25.


MEDIROM Healthcare Technologies  (NAS:MRM) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


MEDIROM Healthcare Technologies 1-Year Sharpe Ratio Related Terms


MRM vs EJH, DROR, EVTK: 1-Year Sharpe Ratio Comparison

For the Personal Services subindustry, MEDIROM Healthcare Technologies's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MEDIROM Healthcare Technologies 1-Year Sharpe Ratio vs Personal Services Industry

For the Personal Services industry and Consumer Cyclical sector, MEDIROM Healthcare Technologies's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where MEDIROM Healthcare Technologies's 1-Year Sharpe Ratio falls into.


MRM
53GF Score
MEDIROM Healthcare Technologies Inc MRM
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MEDIROM Healthcare Technologies 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.25 mean?
MEDIROM Healthcare Technologies (MRM) has a 1-Year Sharpe Ratio of -0.25 as of Aug. 04, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for MEDIROM Healthcare Technologies and its competitors.
Is MEDIROM Healthcare Technologies' 1-Year Sharpe Ratio too high?
MEDIROM Healthcare Technologies' current 1-Year Sharpe Ratio is -0.25. Overall, MEDIROM Healthcare Technologies has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MEDIROM Healthcare Technologies' 1-Year Sharpe Ratio compare to EJH and DROR?
MEDIROM Healthcare Technologies' 1-Year Sharpe Ratio of -0.25 can be compared against companies in the Personal Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Personal Services company?
A good 1-Year Sharpe Ratio depends on the Personal Services industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for MEDIROM Healthcare Technologies and its competitors. MEDIROM Healthcare Technologies's current 1-Year Sharpe Ratio is -0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDIROM Healthcare Technologies stock overvalued right now?
Based on GuruFocus' analysis, MEDIROM Healthcare Technologies (MRM) is currently considered Possible Value Trap. The stock's GF Value™ is $4.07, compared to a current price of $0.93 — trading 77.1% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.25. MEDIROM Healthcare Technologies' overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For MEDIROM Healthcare Technologies (MRM), the current 1-Year Sharpe Ratio is -0.25 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MEDIROM Healthcare Technologies (MRM) Overvalued in 2026?

Based on GuruFocus' analysis, MEDIROM Healthcare Technologies stock appears to be undervalued. The current stock price of $0.93 is trading 77.1% below its estimated GF Value™ of $4.07. GuruFocus considers MEDIROM Healthcare Technologies to be Possible Value Trap.

Key valuation signals for MRM:

  • 1-Year Sharpe Ratio: -0.25
  • GF Value™: $4.07 vs. price of $0.93 (77.1% below fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the MRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MEDIROM Healthcare Technologies Business Description

Address 2-3-1 Daiba, 16th Floor, Tradepia Odaiba, Minato-ku, Tokyo, JPN, 135-0091
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
53GF Score

Get the complete analysis for MRM

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.93
Price
$4.07
GF Value